Getting to clinical proof of concept is no longer enough. Exit strategies and investor demands are shifting further downstream to fully commercializable drug products ready for Phase 3 trials and positioned for acquisition by large pharmaceutical partners. PharmaDirections can help transform your investigational drug product into one that is ready for commercial launch or partner due diligence.
We are structured around the critical scientific and technical expertise required to help your investigational drug development program meet the requirements of a market registration (NDA) filing. We have a core staff of pharmaceutical professionals augmented with a vast assembly of deeply experienced scientists, regulatory experts and project managers to plan and carry out your program. To execute in a timely and efficient manner, we have assembled an extensive alliance of pre-qualified resources so we can carefully match resources for each individual project. PharmaDirections offers the right resources at the right time with the capability to deploy the essential resources only when they are needed.
Services for Phase 2/3 and Pre-Launch :
Pharmaceutical Development and CMC (learn more)>
cGMP Manufacturing (learn more)>
Regulatory Affairs and Quality Assurance (learn more)>
